Loss of gp200-MR6 in Breast Cancer
Author Information
Author(s): L Kaklamanis, MI Koukourakis, R Leek, A Giatromanolaki, M Ritter, R Whitehouse, KC Gatter, AL Harris
Primary Institution: John Radcliffe Hospital, Oxford
Hypothesis
The study investigates the expression of gp200-MR6 in primary breast carcinomas and its correlation with tumor parameters and survival.
Conclusion
Loss of gp200-MR6 may allow breast cancer cells to evade immune surveillance, leading to a higher metastatic potential and poorer outcomes.
Supporting Evidence
- 22% of breast cancer cases were positive for gp200-MR6.
- Patients with positive gp200-MR6 expression had a 92% survival rate at 5 years.
- Loss of gp200-MR6 was more frequent in lobular breast cancer cases.
Takeaway
The study found that a protein called gp200-MR6 is often lost in breast cancer, which might help cancer cells grow and spread more easily.
Methodology
The expression of gp200-MR6 was assessed using immunohistochemistry on 110 primary invasive breast cancer specimens, and results were correlated with various tumor parameters and patient survival.
Limitations
The study did not find statistically significant correlations between gp200-MR6 expression and several known prognostic factors.
Participant Demographics
The median age of patients was 53 years, and all had no detectable metastatic disease at presentation.
Statistical Information
P-Value
0.1
Confidence Interval
0.07-1.30
Statistical Significance
p=0.03
Want to read the original?
Access the complete publication on the publisher's website